Azzalure (Botulinum toxin type A)
Azzalure is indicated for the temporary improvement in the appearance of moderate to severe
in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.
We provide Galderma (U.K.) Limited with certain information on who has purchased their products through this website for consumer service/support and safety purposes. A copy of Galderma’s Privacy Notice explaining how your data will be collected, used, and disclosed by Galderma can be found here https://tinyurl.com/galdermaprivacy
Adverse events should be reported
For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
For Ireland, suspected adverse events can be reported via HPRA Pharmacovigilance, www.hpra.ie
Adverse events should also be reported to Galderma (UK) Ltd.
E-mail: Medinfo.firstname.lastname@example.org Tel: +44 (0) 300 3035674